Obesity Drugs Enjoy a Much-Needed Winning Streak: Lisa Jarvis

Several critical advances this month will go a long way toward making obesity drugs more widely available to patients: more consistent access, improved affordability and global conviction that these potentially lifelong treatments are worth the cost to the health-care system.

Resolving those issues matter at both the individual level — enabling people to take drugs that could ultimately save their lives — and the societal one, delivering those treatments without bankrupting the health-care system.

Progress began with the Food and Drug Administration’s approval for Eli Lilly & Co.’s tirzepatide, now known as Zepbound. European regulators took a step closer to their own ...